VistaGen Therapeutics Inc (NASDAQ:VTGN)

2.31
Delayed Data
As of 3:59pm ET
 -0.02 / -0.86%
Today’s Change
0.61
Today|||52-Week Range
3.55
+19.07%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$461.0M

Company Description

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. The company's portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder (SAD); PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD); and AV-101 which the company is developing for the treatment of major depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID), and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Contact Information

VistaGen Therapeutics, Inc.
343 Allerton Avenue
South San Francisco California 94080
P:(650) 577-3600
Investor Relations:
(650) 577-3617

Employees

Shareholders

Other institutional22.85%
Mutual fund holders20.48%
Individual stakeholders0.19%

Top Executives

Shawn K. SinghChief Executive Officer & Director
H. Ralph SnodgrassPresident & Chief Scientific Officer
Jerrold D. DotsonChief Financial Officer, Secretary & VP
Mark A. SmithChief Medical Officer
Ellis WilsonVice President-Global Clinical Operations